Page last updated: 2024-08-05 11:22:55
2,6-diaminopurines
Any aminopurine that has amino substituents at positions 2 and 6, and their substituted derivatives.
ChEBI ID: 38001
Members (6)
| Member | Definition | Role |
|---|---|---|
| (R)-DRF053 | A member of the class of 2,6-diaminopurines that is 2,6-diamiopurine which is substituted by an isopropyl group at position 9 and in which the amino groups at positions 2 and 6 are substituted by a 1-hydroxybutan-2-yl and 3-(pyridin-2-yl)phenyl groups, respectively (the R enantiomer). A cyclin dependent kinase inhibitor, widely used as its hydrochloride hydrate. | (R)-DRF053 |
| 2-amino-n(6)-hydroxyadenine | A 2,6-diaminopurine that is the N(6)-hydroxy derivative of 2,6-diamino-3H-purine. | 2-amino-6-hydroxyaminopurine |
| 2,6-diaminopurine | A member of the class of 2,6-diaminopurines that is 9H-purine in which the hydrogens at positions 2 and 6 are replaced by amino groups. | 9H-purine-2,6-diamine |
| abacavir | A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection. | abacavir |
| cyc 202 | 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors. | seliciclib |
| olomoucine | A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor. | olomoucine |
Research
Studies (2,508)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 62 (2.47) | 18.7374 |
| 1990's | 242 (9.65) | 18.2507 |
| 2000's | 1,159 (46.21) | 29.6817 |
| 2010's | 884 (35.25) | 24.3611 |
| 2020's | 161 (6.42) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 247 (9.09%) | 5.53% |
| Reviews | 211 (7.77%) | 6.00% |
| Case Studies | 103 (3.79%) | 4.05% |
| Observational | 19 (0.70%) | 0.25% |
| Other | 2,136 (78.65%) | 84.16% |